For the estimated millions carrying pathogenic MEFV variants worldwide, the clinical picture may extend well beyond the episodic fever attacks that define familial Mediterranean fever. A large matched-cohort study now quantifies what clinicians have long suspected: FMF is not a siloed autoinflammatory condition but a systemic inflammatopathy with broad and lasting consequences for immune regulation.
Drawing on two decades of electronic health records from Leumit Health Services in Israel, researchers matched 3,324 confirmed FMF patients against 13,296 age-, sex-, and socioeconomically-matched controls and tracked rheumatologic and autoimmune outcomes through 2024. At baseline, FMF was independently associated with Behçet disease, rheumatoid arthritis, fibromyalgia, gout, osteoarthritis, and connective tissue disease — all surviving false discovery rate correction. The longitudinal arm extended these associations, with ankylosing spondylitis emerging among the incident diagnoses over the follow-up period. The composite endpoint — any prespecified rheumatologic or autoimmune diagnosis — was significantly elevated in FMF across the full observation window.
This work matters beyond the rare-disease community. FMF's mechanism centers on chronic pyrin inflammasome dysregulation, which drives sustained IL-1β and IL-18 signaling even between symptomatic attacks. That low-grade inflammatory substrate is now biologically plausible as a seedbed for conditions as diverse as axial spondyloarthropathy and autoimmune thyroid disease. Clinically, this challenges the prevailing management model where colchicine suppresses attacks but the broader immunological milieu remains poorly monitored. The population-based design and 20-year horizon are genuine strengths, as is the 1:4 matching and FDR correction. Limitations include retrospective ICD-9 coding, which may underdiagnose milder autoimmune presentations, and the study's Israeli population, where FMF prevalence and genetic heterogeneity differ from Western cohorts. This is an incremental but well-powered confirmation that FMF warrants longitudinal multisystem rheumatologic surveillance, not just attack management.